EXPRS2 — ExpreS2ion Biotech Holding AB Share News
0.000.00%
Last trade - 00:00- SEK24.46m
- -SEK8.46m
- SEK12.21m
Brief: ExpreS2ion Reports Q2 Loss Of SEK 9.7 Million
Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
Brief: Expres2ion Biotech Holding Q1 2026 Operating Income SEK 6.87 Mln
Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations
Brief: Expres2ion Resolves On Set-Off Issue To One Guarantor
Brief: Expres2ion Biotech Highlights BIO-002 Clinical Data
Brief: ExpreS2ion Biotech Holding Resolves On Rights Issue Of Units For About SEK 53 Mln
Brief: Expres2ion Biotech Holding Q4 Operating Income Up At SEK 3.5 Mln
Brief: ExpreS2ion, Serum Institute Of India Enter Definitive Licensing Agreement For Malaria Vaccines
Brief: Expres2ion Biotech Holding Reports First Immunogenicity Results From Phase I
Brief: Expres2ion Biotech Q2 Operating Income SEK 3.4 Mln
Brief: Expres2ion Biotech Holding Gets About EUR 4.6 Mln For Malaria Vaccine Project
Brief: Expres2ion Signs Deal With DTU For Access To Computerome Supercomputer
Brief: Expres2ion's Associated Company Leads Consortium Awarded USD 12.4 Mln
Brief: Expres2ion Biotech Holding Q1 Operating Income Up At Sek 2,957 Thousand
Brief: Expres2ion Signs Letter Of Intent With Wuxi Vaccines
Brief: Expres2ion Biotech Q4 Operating Income Falls To SEK 2.2 Mln
Brief: Expres2ion, Serum Institute Of India Enter In Term Sheet Regarding Novel Malaria Vaccines
Brief: Expres2ion Biotech Q2 Profit For Period Down At Sek 2.5 Mln